From the Journals

Pot legalization tied to drop in opioid prescribing rates

View on the News

Impact of legal marijuana on opioids needs more study

Results of these two investigations suggest that the legalization of marijuana may help combat the opioid crisis, but more rigorous investigations are needed, according to Kevin P. Hill, MD, and Andrew J. Saxon, MD.

The new studies show an association between state marijuana laws and fewer opioid prescriptions in Medicare and Medicaid populations.

Those findings do support previous investigations of administrative data sets suggesting that cannabis legalization policies are associated with reductions in opioid use and mortality, Dr. Hill and Dr. Saxon said in an editorial.

However, not all studies suggest that cannabis replaces opioid use, according to the authors, who cited a study suggesting an association between illicit cannabis use and subsequent cannabis use.

“The association between illicit cannabis use and opioid use may be different than the association of legalized cannabis use and opioids,” the editorial authors wrote. “Nevertheless, the findings demonstrating that cannabis use is associated with initiation of or increase in opioid use underscores the fact that rigorous scientific studies are needed.”

Those studies should focus not only analysis of policies on legal medical and recreational cannabis but also on clinical trials of cannabis and cannabinoids for chronic pain and other conditions where opioids are used, they added.

One limitation of the studies is that Medicare and Medicaid populations generally represent individuals who are disabled, older, and lower income, limiting the ability to generalize to other demographics, according to the authors.

Nevertheless, the authors wrote, a decrease tied to legal marijuana availability would “dovetail” with preclinical evidence that cannabinoid and opioid receptor systems mediate signaling pathways involved in tolerance, dependence, and addiction.

“These concepts support anecdotal evidence from patients who describe a decreased need for opioids to treat chronic pain after initiation of medical cannabis pharmacotherapy,” the authors wrote.

Kevin P. Hill, MD, is with the division of addiction psychiatry at Harvard Medical School and Beth Israel Deaconess Medical Center, both in Boston. Andrew J. Saxon, MD, is with the Center of Excellence in Substance Abuse Treatment and Education at the VA Puget Sound Healthcare System, and the department of psychiatry and behavioral sciences at University of Washington, both in Seattle. These comments are derived from their editorial (JAMA Intern Med. 2018 Apr 2. doi: 10.1001/jamainternmed.2018.0254). The authors reported no conflicts of interest.



Laws covering medical or recreational use of marijuana are associated with reduced rates of opioid prescribing among federal health care program enrollees, results of two recently published investigations show.

In one study, researchers investigated whether medical cannabis access affected opioid prescribing in Medicare Part D, the federal program that subsidizes cost of prescription drugs and drug insurance premiums.

Opioid prescribing in Part D was lower in states that permitted access to medical cannabis, according to investigator Ashley C. Bradford of the department of public administration and policy the University of Georgia, Athens, and her colleagues.

“Medical cannabis policies may be one mechanism that can encourage lower prescription opioid use and serve as a harm abatement tool in the opioid crisis,” Ms. Bradford and her coauthors wrote in JAMA Internal Medicine.

Medical marijuana laws were associated with a decrease of 2.11 million daily opioid doses yearly from an average of 23.08 million doses yearly in the Medicare Part D population, according to results of the longitudinal analysis daily opioids doses filled in Medicare Part D from 2010 through 2015.

In a second study, medical marijuana laws were associated with lower opioid prescribing rates among Medicaid enrollees.

That finding was consistent with earlier studies looking more broadly at pain prescriptions covered by Medicaid that also showed a reduction, researchers Hefei Wen, PhD, and Jason M. Hockenberry, PhD, wrote in their JAMA Internal Medicine article.


Next Article: